eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK1/2 that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer (NSCLC). The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 1/2 clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. The company was founded in 2012 and is headquartered in San Diego, California.
IPO Year: 2021
Exchange: NASDAQ
Website: effector.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/25/2022 | $20.00 → $16.00 | Outperform | Credit Suisse |
| 1/25/2022 | $20.00 → $6.20 | Buy → Hold | Stifel |
| 1/25/2022 | $33.00 → $8.00 | Market Outperform | JMP Securities |
| 11/9/2021 | $20.00 | Hold → Buy | Stifel |
| 10/12/2021 | $20.00 | Outperform | Credit Suisse |
| 10/4/2021 | $20.00 | Buy | Mizuho |
| 9/21/2021 | $33.00 | Market Outperform | JMP Securities |
| 9/20/2021 | $20.00 | Hold | Stifel |
| 9/13/2021 | $50.00 | Overweight | Cantor Fitzgerald |
SC 13D/A - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)
SC 13G/A - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)
SC 13G/A - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)
SC 13G/A - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)
SC 13G/A - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)
SC 13D/A - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)
SC 13D/A - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)
SC 13D/A - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)
SC 13G - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)
SC 13G/A - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)
4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)
4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)
4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)
4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)
4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)
4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)
4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)
4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)
4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)
4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) today announced that the Company has terminated its employees and will wind down it operations, including seeking potential strategic alternatives for the Company's development programs. This decision was made at a special meeting of the board of directors. Further, as previously disclosed, the Company's securities do not presently meet the continued listing requirements of the Nasdaq Stock Market and its securities would be subject to delisting if the Company fails to regain compliance during the required compliance period. The Company plans to voluntarily request a d
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced a collaboration to conduct an investigator-sponsored trial (IST) evaluating zotatifin in combination with abemaciclib and letrozole in patients with estrogen receptor-positive (ER+) endometrial cancer and low grade serous ovarian cancer at the Dana-Farber Cancer Institute (DFCI) under the direction of Panagiotis Konstantinopoulos, M.D., Ph.D., Director of Translational Research and attending oncologist in the Division of Gynecologic Oncology at
Dose escalation of zotatifin in the ZFA triplet ongoing at 0.14 mg/kg, with RP2D expected in H2 2024 Raised $15.0 million in gross proceeds from registered direct financing, extending cash runway into first quarter of 2025 SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. "We had a productive first quarter marked by continued progress in the zotatifin program, including successful completion of the
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors ("STRIs") for the treatment of cancer, today announced that the Company will present at the Stifel Virtual Oncology Forum on Tuesday, April 16th at 11:30 am ET. A live webcast of the virtual presentation will be available on the "Events and Presentations" page of the Investors section of the Company's website with a replay available for 90 days following the event. For more information, please visit investors.effector.com. About eFFECTOR Therapeutics eFFECTOR is a clinical-stage biopha
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced topline results from the primary analysis of the randomized Phase 2 KICKSTART trial which tested tomivosertib or placebo, each combined with pembrolizumab, as frontline treatment for patients with non-small cell lung cancer (NSCLC) with PD-L1 ≥50%. Based on 36 events, the hazard ratio for progression free survival (PFS, the primary endpoint of the study) using a stratified Cox proportional hazards model was 0.62 (95% confidence intervals 0.3
Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC) expected in early April 2024 Median progression free survival (mPFS) of 7.4 months in the ZFA expansion cohort evaluating zotatifin in combination with fulvestrant and abemaciclib in heavily pretreated patients Received U.S. FDA Fast Track designation for zotatifin in combination with fulvestrant and abemaciclib for treatment of ER+/HER2- advanced metastatic breast cancer Raised $15.0 million in gross proceeds from registered direct financing, extending cash runway into first quarter of 2025 SOLANA BEACH, Calif. and REDWOOD CITY, Calif., March 25, 2
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors ("STRIs") for the treatment of cancer, today announced that Steve Worland, Ph.D., president, and chief executive officer of eFFECTOR, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14th at 10:40 am ET. A live webcast of the virtual presentations will be available on the "Events and Presentations" page of the Investors section of the Company's website with a replay available for 90 days following the event. For more information, please vi
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) (the "Company"), a leader in the development of selective translation regulator inhibitors ("STRIs") for the treatment of cancer, today announced that it has closed its previously announced registered direct offering with a new healthcare focused institutional investor for the purchase and sale of an aggregate of 1,488,834 shares of its common stock (or common stock equivalents in lieu thereof) and short-term warrants to purchase up to an aggregate of 1,488,834 shares of its common stock at an offering price of $10.075 per share of common stock (or common stock equival
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) (the "Company"), a leader in the development of selective translation regulator inhibitors ("STRIs") for the treatment of cancer, today announced that it has entered into a definitive agreement with a single healthcare focused institutional investor for the purchase and sale of an aggregate of 1,488,834 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 1,488,834 shares of its common stock at an offering price of $10.075 per share of common stock (or common stock equivalent in lieu thereof) and accomp
- Summary of development progress for tomivosertib and zotatifin and a preview of anticipated 2024 milestones- - Review of recently announced interim data from dose escalation and Phase 2 expansion cohorts of zotatifin in ER+ metastatic breast cancer patients- - Webinar to take place on Wednesday, January 24, 2024, at 4:30 pm ET- SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors ("STRIs") for the treatment of cancer, today announced that it will host a virtual investor R&D Day on Wednesday, January 24, 2024, at 4:30 pm ET. The eFFECTOR I
EFFECT - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
EFFECT - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
EFFECT - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
EFFECT - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
15-12G - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
S-8 POS - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
S-8 POS - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
POS AM - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
POS AM - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
POS AM - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
Credit Suisse reiterated coverage of eFFECTOR Therapeutics with a rating of Outperform and set a new price target of $16.00 from $20.00 previously
Stifel downgraded eFFECTOR Therapeutics from Buy to Hold and set a new price target of $6.20 from $20.00 previously
JMP Securities reiterated coverage of eFFECTOR Therapeutics with a rating of Market Outperform and set a new price target of $8.00 from $33.00 previously
Stifel upgraded eFFECTOR Therapeutics from Hold to Buy and set a new price target of $20.00
Credit Suisse initiated coverage of eFFECTOR Therapeutics with a rating of Outperform and set a new price target of $20.00
Mizuho initiated coverage of eFFECTOR Therapeutics with a rating of Buy and set a new price target of $20.00
JMP Securities initiated coverage of eFFECTOR Therapeutics with a rating of Market Outperform and set a new price target of $33.00
Stifel initiated coverage of eFFECTOR Therapeutics with a rating of Hold and set a new price target of $20.00
Cantor Fitzgerald initiated coverage of eFFECTOR Therapeutics with a rating of Overweight and set a new price target of $50.00
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) today announced that the Company has terminated its employees and will wind down it operations, including seeking potential strategic alternatives for the Company's development programs. This decision was made at a special meeting of the board of directors. Further, as previously disclosed, the Company's securities do not presently meet the continued listing requirements of the Nasdaq Stock Market and its securities would be subject to delisting if the Company fails to regain compliance during the required compliance period. The Company plans to voluntarily request a d
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors ("STRIs") for the treatment of cancer, today announced the addition of Caroline Loewy to its Board of Directors and her election as Chair of the Board's Audit Committee. Concurrent with Ms. Loewy's appointment, current Board member John Smither has resigned from the Board. "We are tremendously fortunate to welcome Caroline given her extensive experience as an executive and board member at multiple biopharmaceutical companies," remarked Steve Worland, Ph.D., president and chief executive office
- Key executive appointments: Douglas Warner, M.D., as CMO & Mayank Gandhi, M.D., as CBO – - Cohort treating ER+ breast cancer with combination of zotatifin, fulvestrant and abemaciclib has been expanded from 7 patients to 18 patients - - Initiated dosing and completed enrollment in second cohort of Phase 1b clinical trial of zotatifin for the treatment of COVID-19 - SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the third quarter ended
SAN DIEGO and REDWOOD CITY, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors ("STRIs") for the treatment of cancer, today announced it has appointed Mayank J. Gandhi, M.D., as chief business officer. Dr. Gandhi will lead eFFECTOR's corporate growth strategy, business development and partnership opportunities. "Mayank is an accomplished leader with extensive experience in the biopharmaceutical industry including corporate development, partnering, product development and commercialization," said Steve Worland, Ph.D., president and chief executive officer of eFFECTOR. "Mayank will b
Presented positive interim results at ASCO 2022 from ongoing zotatifin Phase 1/2 dose escalation and expansion trial Appointed Doug Warner, M.D., as chief medical officer SAN DIEGO and REDWOOD CITY, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2022, and provided a corporate update. "We made significant progress in our clinical programs during the second quarter, and we are thrilled to welcome our new chief medical officer, Doug Warner, who joins at an optimal tim
SAN DIEGO and REDWOOD CITY, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors ("STRIs") for the treatment of cancer, today announced it has appointed Douglas Warner, M.D., as chief medical officer. Dr. Warner will develop strategies to continue advancing eFFECTOR's two clinical-stage STRIs into advanced and potentially registrational trials. "Dr. Warner has extensive experience in oncology therapeutic development, and his expertise designing and executing clinical trials across all developmental stages, especially Phase 3, will be invaluable as we continue to advance our pipeline i
SAN DIEGO and REDWOOD CITY, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced the appointment of Kristen Harrington-Smith, Senior Vice President & Chief Commercial Officer at ImmunoGen, to the company's board of directors. Concurrent with Ms. Harrington-Smith's appointment, Jonathan Root, M.D., has resigned from the company's board of directors. "Kristen is an exceptional strategic thinker with a track record of success launching novel products in oncology," said Steve Worland, President and Chief Executive Officer of eFFECTOR. "Her tw
• Continuing to enroll patients in Phase 2b KICKSTART study of tomivosertib in combination with pembrolizumab, a U.S. Food and Drug Administration (FDA) approved PD-1 inhibitor • Selected recommended Phase 2 dose (RP2D) of zotatifin for continued development for patients with certain solid tumors • Commenced enrollment in Phase 2a indication-specific expansion cohorts of zotatifin study • Debuted as publicly-traded next-generation oncology company under symbol EFTR SAN DIEGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financia
SAN DIEGO, Nov. 01, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced the appointment of Barbara Klencke, M.D., Chief Medical Officer and Chief Development Officer at Sierra Oncology, to the company's board of directors. Concurrent with Dr. Klencke's appointment, Larry Lasky, Ph.D., has resigned from the company's board of directors. "Dr. Klencke is a phenomenal leader with an extensive track record of success in oncology drug development, from R&D through approval and commercialization," said Steve Worland, President and Chief Executive Officer of eFF
Partial responses observed in 5 of 19 (26%) evaluable patients treated with zotatifin 0.07 mg/kg combined with fulvestrant and abemaciclib (ZFA triplet) in heavily pretreated populationPartial response observed in 1 of 3 (33%) patients treated with zotatifin 0.1 mg/kg combined with fulvestrant (ZF doublet)Both combinations were generally well tolerated with large majority of adverse events Grade 1 or 2Company will host a virtual investor call on June 4, 2023, to discuss the data and clinical progress SOLANA BEACH and REDWOOD CITY, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors ("
Updated data from two fully enrolled Phase 2 expansion cohorts testing zotatifin-based combinations in estrogen receptor-positive (ER+) Metastatic Breast Cancer to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023 on June 4, 2023 Company will host conference call to discuss results and further development of zotatifin during ASCO Annual Meeting 2023 Zotatifin is being evaluated in patients with ER+, human epidermal growth factor receptor 2-negative (HER2-) breast cancer in a pre-operative setting through clinical collaboration with Jennifer Caswell-Jin, M.D., Assistant Professor of Medicine at Stanford Medicine SOLANA BEACH and REDWOOD CITY, Calif.
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors ("STRIs") for the treatment of cancer, today announced a poster highlighting results from Phase 2 expansion cohorts of a Phase 1/2 dose escalation and expansion trial with zotatifin in patients with ER+ Metastatic Breast Cancer has been selected for presentation at the American Society of Clinical Oncology ("ASCO") 2023 Annual Meeting. Following the presentation, eFFECTOR will host a conference call to discuss the data. The ASCO website indicates that abstracts will be released on May 25, 2023
Zotatifin continues to show favorable activity profile, including two confirmed partial responses (PR) among seven heavily pretreated subjects who received zotatifin, fulvestrant and abemaciclib (ECBF+A), with good tolerability eFFECTOR to focus on front-line PD-L1 ≥ 50% cohort of KICKSTART trial with tomivosertib in non-small cell lung cancer Management to present results and provide full pipeline update in investor call on January 5, 2023 at 4:30 p.m. ET SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatm
Two partial responses observed in heavily pre-treated ER+ breast cancer patients One ongoing cohort in ER+ breast cancer has been expanded and new expansion cohort planned in ER+ breast cancer patients with Cyclin D amplification Management and key opinion leaders to present results and provide update on expanded development of zotatifin in investor call on June 5th at 7 p.m. ET / 6 p.m. CT SAN DIEGO and REDWOOD CITY, Calif., June 05, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors ("STRIs") for the treatment of cancer, today reported positive interim results of the company's ongoing Phase 1/2
Positive initial data demonstrated pharmacologically relevant exposures Management and key opinion leaders to present complete results and provide update on expanded development of zotatifin in investor call on June 5th at 7 p.m. ET / 6 p.m. CT SAN DIEGO and REDWOOD CITY, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that it will present interim data from its ongoing Phase 1/2 dose escalation and expansion trial of zotatifin in multiple solid tumors in an oral poster presentation at the 2022 American Society of Clinical O
Tomivosertib development strategy updated, including addition of a new cohort in Phase 2b KICKSTART trial in non-small cell lung cancer (NSCLC) evaluating frontline maintenance in PD-L1 ≥1% patient population, representing additional $5 billion U.S. market opportunity First patients dosed in two additional Phase 2 expansion cohorts evaluating zotatifin in combination with sotorasib in KRAS G12C-mutant NSCLC and in combination with abemaciclib and fulvestrant in ER+/HER2- breast cancer Company enters into investment agreement with Lincoln Park Capital for up to $50 million Management to host investor call January 24 at 5 p.m. ET SAN DIEGO and REDWOOD CITY, Calif., Jan. 24, 2022 (GLOBE